Fenofibrate and Metformin Insulin Sensitivity in Type 2 Diabetics Study

Summary

Double-blind, randomized placebo-controlled study in type 2 diabetes and dyslipidemic patients.Patients will be randomized to one of four treatment arms for 16 weeks: placebo, fenofibrate, metformin, or metformin and fenofibrate combination.

Timeline

Start

2006-10

Primary completion

—

Completion

2007-07

Outcome

Outcome not reported

Stopped (Enrollment): “The study was prematurely terminated, due to difficulties in the recruitment of T2DM patients who are not under statin therapy at inclusion.”

Drugs

Indications